Cargando…

Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles

Filamin-A (FLNA) plays a crucial role in somatostatin receptor (sst) subtype-2 signaling in somatotropinomas. Our objective was to investigate the in vivo association between FLNA and sst2 expression, sst5 expression, dopamine receptor subtype-2 (D2) expression, somatostatin receptor ligand (SRL) re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coelho, Maria Caroline Alves, Vasquez, Marina Lipkin, Wildemberg, Luiz Eduardo, Vázquez-Borrego, Mari C., Bitana, Luciana, Camacho, Aline Helen da Silva, Silva, Débora, Ogino, Liana Lumi, Ventura, Nina, Sánchez-Sánchez, Rafael, Chimelli, Leila, Kasuki, Leandro, Luque, Raul M., Gadelha, Mônica R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361919/ https://www.ncbi.nlm.nih.gov/pubmed/30718563 http://dx.doi.org/10.1038/s41598-018-37692-3

Ejemplares similares

Molecular evidence and clinical importance of β‐arrestins expression in patients with acromegaly
por: Coelho, Maria Caroline Alves, et al.
Publicado: (2018)

The Future of Somatostatin Receptor Ligands in Acromegaly
por: Gadelha, Monica R, et al.
Publicado: (2021)

Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response
por: Kasuki, Leandro, et al.
Publicado: (2016)

miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
por: Henriques, Daniel G., et al.
Publicado: (2023)

gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
por: Wildemberg, Luiz Eduardo, et al.
Publicado: (2021)

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands
por: Henriques, Daniel G., et al.
Publicado: (2022)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

The genetic background of acromegaly
por: Gadelha, Mônica R., et al.
Publicado: (2017)

Novel therapies for acromegaly
por: Maia, Bernardo, et al.
Publicado: (2020)

Determinants of morbidities and mortality in acromegaly
por: Kasuki, Leandro, et al.
Publicado: (2019)

Acromegaly and Colorectal Neoplasm: An Update
por: Kasuki, Leandro, et al.
Publicado: (2022)

Pulmonary function testing and chest tomography in patients with acromegaly
por: Camilo, Gustavo Bittencourt, et al.
Publicado: (2013)

On the Functional Capacity and Quality of Life of Patients with Acromegaly: Are They Candidates for Rehabilitation Programs?
por: Guedes da Silva, Débora Pedroza, et al.
Publicado: (2013)

E‐cadherin expression is associated with somatostatin analogue response in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2019)

AIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation
por: Araujo, Paula Bruna, et al.
Publicado: (2017)

Clinical and functional variables can predict general fatigue in patients with acromegaly: an explanatory model approach
por: Michalski, André da Cunha, et al.
Publicado: (2019)

Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
por: Marques, Nelma Veronica, et al.
Publicado: (2023)

Growth hormone-releasing hormone-secreting pulmonary neuroendocrine tumor associated with pituitary hyperplasia and somatotropinoma
por: Lamback, Elisa B., et al.
Publicado: (2021)

Effects of combination therapy: somatostatin analogues and dopamine agonists on GH and IGF1 levels in acromegaly
por: VALEA, ANA, et al.
Publicado: (2015)

SUN-322 Worsening of Carcinoid Syndrome during Lutetium Therapy in a Patient with Bronchial Carcinoid and Acromegaly
por: Baranski Lamback, Elisa, et al.
Publicado: (2019)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

Apoplexy in sporadic pituitary adenomas: a single referral center experience and AIP mutation analysis
por: Fialho, Christhiane, et al.
Publicado: (2021)

Brazilian multicenter study on pegvisomant treatment in acromegaly
por: Boguszewski, Cesar L., et al.
Publicado: (2019)

Glycemic profile in patients with acromegaly treated with somatostatin analogue
por: Valea, A, et al.
Publicado: (2015)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
por: Chin, Sang Ouk, et al.
Publicado: (2019)

Association of Pathology Markers with Somatostatin Analogue Responsiveness in Acromegaly
por: Kontogeorgos, George, et al.
Publicado: (2022)

Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly
por: Gil, Joan, et al.
Publicado: (2021)

Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study
por: Berton, Alessandro Maria, et al.
Publicado: (2022)

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022)

Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience
por: Gadelha, Mônica, et al.
Publicado: (2023)

Correlations between forced oscillation technique parameters and pulmonary densitovolumetry values in patients with acromegaly
por: Camilo, G.B., et al.
Publicado: (2015)

Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly
por: Ciganoka, Darja, et al.
Publicado: (2011)

The Effect of Long Acting Somatostatin Analogue SMS 201-995 in Acromegaly
por: Choi, Chul Joon, et al.
Publicado: (1987)

The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues
por: Alvarez-Escola, Cristina, et al.
Publicado: (2016)

Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues
por: Follin, Cecilia, et al.
Publicado: (2016)

Somatostatin Receptor Subtype Expression in Patients with Acromegaly and Complicated Clinical Course
por: Pichler, Robert, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lkdgqbqjhn0so07o5jom019f50